Charles Fuchs, MD: First-Line Treatments in Unresectable Colon Cancer
What are the first-line treatments for patients diagnosed with advanced, unresectable colon cancer?
For a newly-diagnosed patient with metastatic colorectal caner, there are several options. Firstly, with regard to the chemotherapy backbone, one could either consider FOLFOX, namely an oxaliplatin-based regimen, or FOLFIRI, an irinotican-based regimen. What we know from the literature is that those two chemotherapy combinations have equivalent efficacy. They have some differences in toxicities, but both relatively well-tolerated and perfectly reasonable frontline regimens.
My own preference has historically been to start with FOLFOX, but I think FOLFIRI is an excellent regimen. With regard to the biologics that should be added to these regimens, and I think there's compelling evidence to add a biologic, bevacizumab is a very appropriate addition. That is the drugs that target the EGFR pathway have considering efficacy and there are several now approved. The combination of FOLFOX or FOLFIRI and bevacizumab is reasonable.
Unresectable Colon Cancer: Case 1
68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.
Sotorasib/Panitumumab Combo Improves PFS in Refractory KRAS G12C+ mCRC
October 23rd 2023The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C mutations.
Read More
T-IELs Could Hold the Key for CRC Immunotherapy
October 10th 2023Researchers identified different functions of groups of intraepithelial T cells (T-IELs) throughout the gastrointestinal tract, which could help inform future immunological treatment for patients with colorectal cancer.
Read More
CAPOX Regimen Appears Noninferior to FOLFOX in CRC
October 8th 2023The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.
Read More
